Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T49814
(Former ID: TTDI01534)
|
|||||
| Target Name |
Bacterial Deoxyribonucleic acid (Bact DNA)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 6 Target-related Diseases | + | ||||
| 1 | Amoebiasis [ICD-11: 1A36] | |||||
| 2 | Blastomycosis [ICD-11: 1F22] | |||||
| 3 | Bowel habit change [ICD-11: ME05] | |||||
| 4 | Crohn disease [ICD-11: DD70] | |||||
| 5 | Sepsis [ICD-11: 1G40-1G41] | |||||
| 6 | Urinary tract infection [ICD-11: GC08] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 6 Approved Drugs | + | ||||
| 1 | Clofazimine | Drug Info | Approved | Crohn disease | [2] | |
| 2 | Furazolidone | Drug Info | Approved | Diarrhea | [3] | |
| 3 | Hydroxystilbamidine Isethionate | Drug Info | Approved | Blastomycosis | [4] | |
| 4 | Metronidazole | Drug Info | Approved | Amoebiasis | [5] | |
| 5 | Nitrofurantoin | Drug Info | Approved | Urinary tract infection | [6] | |
| 6 | Proflavine | Drug Info | Approved | Sepsis | [7] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | MGB-BP-3 | Drug Info | Phase 2 | Clostridium infection | [8] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | Clofazimine | Drug Info | [9] | |||
| 2 | Furazolidone | Drug Info | [10] | |||
| 3 | Hydroxystilbamidine Isethionate | Drug Info | [1] | |||
| 4 | Metronidazole | Drug Info | [11] | |||
| Breaker | [+] 1 Breaker drugs | + | ||||
| 1 | Nitrofurantoin | Drug Info | [12] | |||
| Binder | [+] 2 Binder drugs | + | ||||
| 1 | Proflavine | Drug Info | [13] | |||
| 2 | MGB-BP-3 | Drug Info | [14] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42. | |||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019500. | |||||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011270. | |||||
| REF 4 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009166. | |||||
| REF 5 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018517. | |||||
| REF 6 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009175. | |||||
| REF 7 | Drug information of Proflavine, 2008. eduDrugs. | |||||
| REF 8 | ClinicalTrials.gov (NCT03824795) Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD. U.S. National Institutes of Health. | |||||
| REF 9 | The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4. | |||||
| REF 10 | Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5. | |||||
| REF 11 | DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8. | |||||
| REF 12 | On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. | |||||
| REF 13 | Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19. | |||||
| REF 14 | Clinical pipeline report, company report or official report of MGB Biopharma. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.